Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Morgan Stanley's analyst, Terence Flynn, sticks to his guns with a Hold rating for Vertex Pharmaceuticals, pegging the price ...